The journal retracts the article, “The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models” [1], cited above. Here, CRTC1 is linked to central nervous system cancer.